Kaos Capital presses for Capricor governance change as Eli Lilly doubles down on vaccines

Shareholders are applying pressure on multiple fronts in biopharmaceuticals, with two separate threads standing out: governance and strategic direction at Capricor, and technology-led research and development efforts at larger peers. The developments were highlighted in a biopharma industry report carried by Yahoo Finance.

For Capricor, the activist angle centers on Kaos Capital’s stated desire for what it called a “governance reset.” The company is associated with Duchenne muscular dystrophy cell therapy efforts, and Kaos Capital is seeking changes that would alter the strategic course of the Duchenne cell therapy maker.

The activist push, as described in the report, suggests a disagreement with how Capricor is positioned to execute its plans. While the report characterizes the intent as governance-related, it does not lay out specific demands in the material provided here, such as proposed board composition, named candidates, or a detailed alternative roadmap that Kaos Capital would install.

Elsewhere, Eli Lilly is described as “diving deeper into vaccines,” pointing to continued investment and prioritization in vaccine development. The report frames the move as part of a broader shift in how major drugmakers are allocating resources, with vaccines increasingly viewed as a strategic platform rather than a niche therapeutic area.

Eli Lilly’s vaccine push also reflects intensifying competition in preventive medicine, where speed of platform iteration and manufacturing scale can matter as much as early clinical results. Still, the report does not specify which vaccine programs are being added or expanded, whether Lilly is emphasizing any particular indication, or what near-term milestones it is aiming to hit.

The same industry roundup also references Bristol Myers’ efforts to build an “AI-powered” discovery engine. The description indicates that the company is pursuing a technology-driven approach to earlier-stage drug discovery, a theme that has become increasingly common as large biopharma companies seek to reduce cycle times and increase the throughput of candidate generation.

The report does not provide technical details on how Bristol Myers’ AI engine functions, what data sources it uses, or what specific discovery steps it is meant to accelerate. It also does not quantify progress, such as which programs have benefited or what timelines have changed as a result.

Taken together, the picture is of an industry that is being shaped both from the outside and the inside. Activists want governance and strategy aligned with performance expectations, while major developers pursue platform advantages in areas like vaccines and AI-enabled discovery. The immediate catalysts for investors and observers will likely be how each company responds: whether Capricor engages with Kaos Capital’s proposals and whether Lilly and Bristol Myers provide clearer program-level disclosures tied to their stated priorities.